PerkinElmer Genetics, Inc. – Trademark Portfolio
Entity Type: 03
PerkinElmer Genetics, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include CNGNOME, STEPONE, and SCREEN TODAY FOR A BETTER TOMORROW. The owner is based in Pittsburgh, PA.
250 Industry Drive, Suite 400
Pittsburgh, PA 15275
Showing of trademarks Trademarks
Trademark Classifications
PerkinElmer Genetics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does PerkinElmer Genetics, Inc. have?
PerkinElmer Genetics, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 cancelled.
What trademark classes does PerkinElmer Genetics, Inc. file in?
PerkinElmer Genetics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are PerkinElmer Genetics, Inc.'s most well-known trademarks?
PerkinElmer Genetics, Inc.'s registered trademark portfolio includes well-known marks such as CNGNOME, STEPONE, and SCREEN TODAY FOR A BETTER TOMORROW. These are among 3 currently registered trademarks in the portfolio.
What is PerkinElmer Genetics, Inc.'s trademark registration success rate?
PerkinElmer Genetics, Inc. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.